 Methodology
 Open Access
 Published:
A robust design for identification of the Parasite Clearance Estimator
Malaria Journal volume 12, Article number: 410 (2013)
Abstract
Background
Antimalarial efficacy needs to be monitored continually to ensure optimal dosing in the face of emerging antimalarial drug resistance. The efficacy of artemisinin based combination therapies (ACT) is assessed by repeated measurements of parasite density in the blood of patients following treatment. Parasite density is measured from a capillary or venous blood sample, but this can be logistically and ethically challenging if multiple samples are required within a short time period. The aim of this work was to apply optimal design theory to derive clinically feasible blood sampling schedules from which parasite clearance could be defined using the Parasite Clearance Estimator (PCE), a recently developed tool to identify and quantify artemisinin resistance.
Methods
Robust Toptimal design methodology was applied to offer a sampling schedule that allows for discrimination across models that best describe an individual patient’s parasitetime profile. The design was based on typical parasitetime profiles derived from the literature combined with key sampling constraints of no more than six samples per patient within 48 hours of initial treatment. The design was evaluated with a simulationestimation procedure that implemented the PCE.
Results
The optimal sampling times (sampling windows) were: 0 (0 to 1.1), 5.8 (4.0 to 6.0), 9.9 (8.4 to 11.5), 24.8 (24.0 to 24.9), 36.3 (34.8 to 37.2) and 48 (47.3, 48.0) hours post initial treatment. The simulationestimation procedure showed that the design supported identification of the appropriate method by the PCE to determine an individual’s parasite clearance rate constant (the main output calculation from the PCE).
Conclusions
The proposed sampling design requires six samples per patient within the first 48 hours. The derived design requires validation in a real world setting, but should be considered for future studies that intend to employ the PCE.
Introduction
The artemisinin derivatives remain potent agents in the antimalarial armamentarium. However, their efficacy is under threat from emerging evidence documenting reduced parasite sensitivity in Cambodia [1, 2]. This alarming finding provides motivation for conducting more efficacy and pharmacokineticpharmacodynamic (PKPD) studies of these important drugs to monitor their efficacy and reassess current dosing regimens.
A key pharmacodynamic measure of antimalarial drug efficacy is the measurement of parasite density in the peripheral blood, usually determined by a finger prick sample and examination of a drop of blood by microscopy. A variety of parameters are available for quantifying the drug efficacy on parasite dynamics. Repeated measures of parasitaemia can be used to determine the parasite clearance time, defined as the time from the start of treatment to a parasite count below the microscopy limit of detection. Analytical approaches to quantifying an individual’s parasite clearance time vary although recently interest has focused on the Parasite Clearance Estimator (PCE) [3], a tool developed specifically to calculate a rate constant (the parasite clearance rate constant, PCRC) from repeated measures of parasitaemia. In brief, the PCE calculates the PCRC by first fitting linear, quadratic and cubic regression models to an individual’s observed (log) parasitetime data, and identifies which of these models provides the best fit. If the best model is linear, the PCE declares the PCRC as the absolute value of the estimated slope. If the best model is quadratic or cubic, the PCE performs an algorithm to determine if the model’s predictions exhibit an initial delay in parasite decline, and the PCRC is calculated as the absolute value of the estimated slope from a linear model fitted to the subset of best model predictions that display linearity over time. The PCRC is considered a robust proxy measure for an individual’s parasite clearance time [4].
For the PCE to determine the appropriate method for calculating an individual’s PCRC, blood sampling needs to be frequent enough to provide means for model discrimination (across loglinear, quadratic and cubic parasitetime profiles) and allow the PCE to detect delays in parasite reduction. Determining blood sampling schedules in patients with uncomplicated falciparum malaria treated with artemisininbased combination therapies (ACT) can be challenging, as it can be logistically and ethically difficult to impose intensive schedules over the timespan where parasites are above the limit of microscopic detection (approximately 48 hours post initial treatment [5–8]). Therefore a sampling schedule for the PCE must be clinically feasible within the first 48 hours of treatment and offer sufficient information for appropriate implementation.
Toptimal designs offer a sampling schedule that allows for discrimination across competing models. In brief, an iterative procedure is used to achieve sampling times that capture the largest differences across the specified competing profiles. To date, analytical approaches to designing efficacy (i.e. pharmacodynamics, or PD) studies, such as optimal design methods, have not been applied to the study of treatment response following antimalarial therapy. The aim of the current study was to use optimal design methodology to determine a clinically feasible sampling design for future studies that intend to use the PCE.
Methods
Determination of the design for the Parasite Clearance Estimator
The PCE is defined on the basis of the PCRC, which is the slope of the log (base e) parasitaemiatime relationship for an individual patient, accounting for any initial delay in parasite reduction [3]. Figure 1 provides a visual aid to the PCE. For full details of the PCE, including the algorithm it performs to detect an initial delay in parasite reduction, see Additional file 1 and [3].
As a key aspect of the PCE is determining a “best” model that describes the log parasitetime relationship for an individual, a robust Toptimal design was determined for future studies that intend to use the PCE. A robust Toptimal design determines a sampling schedule that provides means for model discrimination and has the additional benefit of not assuming one of the models is “true”. For further technical details of robust Toptimality see [9]. The design was derived based on the following specifications: (i) six samples per person over the first 48 hours of treatment (the suggested minimum for model exploration [3]), and (ii) “typical” quadratic and cubic log parasitetime profiles that were presented graphically in [3] (i.e. Figure one in [3]). Flegg et al. also presented a “typical” linear parasitetime profile, but this was not considered in the optimization procedure since sampling times at 0 and 48 hours (both taken routinely) would provide enough information for detection of this model. It was not stated in [3] how any of these “typical” profiles were derived, but it was assumed that they were accurate summaries of observed data. Since parameter values for the typical profiles were not reported in [3], parameter values for the quadratic and cubic profiles were obtained by digitizing points from their respective plots in [3] and fitting quadratic and cubic regression models (respectively) to these digitized data in Stata [10]. The results from these analyses are given below in Equation 1. In the equation, P represents total parasite count and t indicates time (hours post initial treatment).
Using these results, the following algorithm developed by Vajjah and Duffull [9] was written and implemented in R [11]:

1.
Log parasite counts were simulated from the quadratic model (with residual error) at a prespecified design (0, 6, 10, 24, 36 and 48 h; based on visual inspection of the typical profiles).

2.
A cubic model was fitted to the counts simulated from the quadratic model.

3.
Simulated annealing was used to find the design points that maximized the residual sum of squared differences between the counts arising from the quadratic and cubic models.

4.
Log parasite counts were simulated from the cubic model (with residual error) at the optimized design points obtained from step 3.

5.
A quadratic model was fitted to the counts simulated from the cubic model.

6.
Simulated annealing was used to find the design points that maximized the residual sum of squared differences between the counts arising from the quadratic and cubic models.

7.
Step 1 was repeated, using the design points obtained in step 6 and parameters obtained in steps 5 and 2.
The process was repeated until a convergence of design points in step 6 was achieved between successive iterations. Convergence was declared when the maximum difference for any design point was less than 0.1 hours.
To provide flexibility with taking samples in the field, sampling windows, which are time intervals that include the optimal sampling times, were derived. The windows were determined using the evaluation procedure described in the next section.
Evaluation of the design for the Parasite Clearance Estimator
The derived Toptimal design for the PCE was evaluated using a simulationestimation procedure to assess the ability of the design to support the PCE in identifying the correct method to calculate an individual’s PCRC. At the time this work was completed the PCE was not publicly available, hence the following procedure was coded and implemented in R:

1.
Log parasite count data were simulated at the optimal sampling times from either a linear, quadratic or cubic model with residual error (based on the analysis of digitized data described above) and betweensubject variances (BSVs) on the model parameters. The incorporation of BSVs was done to provide a posthoc assessment of the robustness of the design, as BSVs were not considered in the optimization procedure. Values for the BSVs were chosen based on plausible simulated log parasitetime profiles (displayed in the Results section; see Additional file 1 for full details of the simulation models). The structural model (linear, quadratic or cubic) the data were simulated from was considered the “true” model.

2.
Linear, quadratic and cubic models were fitted to the simulated data in step 1.

3.
The model with the lowest AIC in step 2 was considered the “best” model.

4.
The procedure to identify the method to calculate the PCRC (steps 2 and 3 from the PCE calculation algorithm in Additional file 1) was adopted.
An individual iteration of this procedure was considered successful if the appropriate method for calculating the PCRC was identified. For example, if the linear model was the “true” model, then the PCE should determine that the PCRC should be the absolute value of the estimated slope from a linear model (with a lag of 0). If the “true” model was quadratic or cubic, then the PCE should detect the lags in these models, and hence determine that the PCRC should be the absolute value of the estimated slope from a linear model fitted to the subset of model predictions that display linearity over time. See Figure 1 for a visual guide. For each “true” model, the simulationestimation process above was repeated 1000 times (i.e. 1000 individual log parasitetime profiles were simulated and then evaluated) and the percentage of successful runs (i.e. the percentage of the 1000 individuals where the appropriate method for calculating PCRC was identified) was recorded. An acceptable success percentage was set to 85%.
Sampling windows for this design were determined using the evaluation procedure. First, lower and upper bounds for each optimal sampling time were specified based on visual inspection of the typical profiles and clinical feasibility. Second, a random sample was taken from within each window, creating a new design, and this new design was then evaluated with the simulationestimation procedure described above. This process was repeated 100 times (i.e. 100 designs were evaluated with the simulationestimation procedure above), and the windows were deemed acceptable if the median percentage of successful runs across the 100 designs was at least 80%.
Results
Table 1 displays the optimal sampling times and corresponding sampling windows determined by robust Toptimal methods. Figure 2 displays the design graphically, as well as the competing quadratic and cubic log parasitetime profiles the design was based on (a typical linear log parasitetime profile is also displayed). The optimization procedure captured the potential “lag” and “tail” phases of the profiles as suggested by [3], as well as the routine sampling times of 0, 24 and 48 hours.
Figure 3 displays summaries of the simulated log parasitetime profiles used for the evaluation procedure and Table 2 reports the results from implementing the procedure. When the “true” log parasitetime profile was specified as a linear model, the appropriate method to calculate the PCRC (the absolute value of the estimated slope from a linear model) was identified in 94% of the simulated individual log parasitetime profiles. When the true log parasitetime profile was specified as quadratic, the appropriate method to calculate the PCRC (the absolute value of the estimated slope from a linear model fitted to the quadratic model predictions after the lag phase) was identified in 96% of the simulated profiles. When the “true” log parasitetime profile was specified as cubic, the correct method for calculating the PCRC (the absolute value of the estimated slope from a linear model fitted to the cubic model predictions between the initial and late lag phases) was identified in 86% of the simulated profiles.
Discussion
For the first time, optimal design methods have been applied to the study of treatment response following antimalarial therapy. The derived robust Toptimal design for the PCE provided sufficient means for identifying appropriate sampling from which to calculate the PCRC. The design is clinically feasible, requiring only six samples per patient over the first 48 hours of treatment; two samples less than that suggested previously to detect an initial lag in parasite reduction [4]. However the precise timing of the proposed schedule times may provide logistical challenges in the setting of clinical field trials. Hence further evaluation will be required to demonstrate that the proposed design is robust, efficient and flexible.
The design was based on models that were fitted to digitized data derived from the typical log parasitetime profiles presented in [3]. Although this could be viewed as a limitation (i.e. the models were not fitted to observed data), this was one of the few ways parameter values for the profiles could be obtained, since estimates of the model parameters for these profiles were not reported in [3]. After the completion of this work, a personal communication with Flegg et al. revealed that the parameter estimates from the analyses of digitized data were in fact very similar to the parameter estimates from models fitted to observed parasitetime data, thus providing support for the models used for the designs. Another limitation of this study was that the optimization procedure was sensitive to initial design specification. However, the evaluation procedure, which simulated parasitetime profiles from models that incorporated both between and withinindividual variability, showed that the derived design provided sufficient support to the PCE in identifying the appropriate method for calculating an individual’s PCRC. This empirical finding provides support for the design proposed in this paper, and highlights the importance of empirical evaluation in optimal design development. Furthermore, the evaluation procedure enabled derivation and assessment of sampling windows, which may provide more informative windows than those defined by less rigourous methods (e.g. visual inspection alone). Lastly, the derived design is very similar to a reduced sampling scheme determined by Flegg et al. that yielded accurate and reliable estimation of parasite halflife via the PCE [12].
Conclusions
The proposed robust Toptimal design provides guidance for investigators wishing to employ the PCE, now available online from WWARN [13]. As more parasitetime profile data become available from different malaria endemic regions where efficacy of the artemisinin derivatives is declining, the proposed sampling strategy can be reevaluated and possibly revised to accommodate potentially longer lag phases and/or delayed parasite clearance times.
References
 1.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455467. 10.1056/NEJMoa0808859.
 2.
Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, AlSaai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NPJ, White NJ, Anderson TJC, Nosten F: Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012, 379: 19601966. 10.1016/S01406736(12)60484X.
 3.
Flegg JA, Guerin PJ, White NJ, Stepniewska K: Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011, 10: 33910.1186/1475287510339.
 4.
White NJ: The parasite clearance curve. Malar J. 2011, 10: 27810.1186/1475287510278.
 5.
McGready R, Phyo AP, Rijken MJ, Tarning J, Lindegardh N, Hanpithakpon W, Than HH, Hlaing N, Zin NT, Singhasivanon P, White NJ, Nosten F: Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012, 73: 467477. 10.1111/j.13652125.2011.04103.x.
 6.
Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA: Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J. 2011, 10: 18110.1186/1475287510181.
 7.
Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA: Optimal designs for population pharmacokinetic studies of the partner drugs coadministered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malar J. 2012, 11: 14310.1186/1475287511143.
 8.
Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NPJ, White NJ, Nosten F, Lindegardh N: Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Ch. 2012, 56: 57645773. 10.1128/AAC.0124212.
 9.
Vajjah P, Duffull SB: A generalisation of Toptimality for discriminating between competing models with an application to pharmacokinetic studies. Pharm Stat. 2012, 11: 503510. 10.1002/pst.1542.
 10.
StataCorp: Stata Statistical Software: Release 11. 2009, College Station: StataCorp LP
 11.
R Development Core Team: R: A Language and Environment for Statistical Computing. 2012, Vienna: R Foundation for Statistical Computing, http://www.rproject.org/. [ISBN3900051070]
 12.
Flegg JA, Guerin PJ, Nosten F, Ashley EA, Dondorp AM, Fairhurst RM, Socheat D, Borrmann S, Björkman A, Mårtensson A, Mayxay M, Newton P, Bethell D, Se Y, Noedl H, Diakite M, Djimde AA, Hien TT, White NJ, Stepniewska K: Optimal sampling designs for accurate estimation of parasite clearance in the context of artemisinin resistance. Malar J. 2013 in press
 13.
Worldwide Antimalarial Resistance Network: The Parasite Clearance Estimator. 2013,http://www.wwarn.org/toolkit/datamanagement/parasiteclearanceestimator,
Acknowledgements
This work was funded by a project grant from the Australian National Health and Medical Research Council (NHMRC; 566855). KMJ was funded by a NHMRC PhD scholarship at the time this work was completed. The MahidolOxford Tropical Medicine Research Unit and the PKPDia collaboration are supported by the Wellcome Trust.
Author information
Additional information
Competing interests
This article was submitted to Malaria Journal in partnership with Flegg et al., who jointly submitted a separate article addressing the topic of this paper using a different methodological approach [12]. The work presented in this paper was completed independently of Flegg et al., except where noted in the Discussion. The joint submission of this article and the article by Flegg et al. to Malaria Journal was agreed upon by all authors of this paper and Flegg et al. The authors of this paper declare no other competing interests.
Authors’ contributions
KMJ and JAS conceived the project. KMJ implemented and evaluated the designs. KMJ wrote the first draft of the manuscript. JAS, SBD, JT and RNP revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Jamsen, K.M., Duffull, S.B., Tarning, J. et al. A robust design for identification of the Parasite Clearance Estimator. Malar J 12, 410 (2013) doi:10.1186/1475287512410
Received
Accepted
Published
DOI
Keywords
 Artemisinin Base Combination Therapy
 Parasite Density
 Parasite Clearance
 Sampling Window
 Sampling Schedule
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.